Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Autor:	Domenico Viola, Hongzhi Li, Xiwei Wu, Flavia Pichiorri, James F. Sanchez, Timothy W. Synold, Steven T. Rosen, Ralf Buettner, Michael Rosenzweig, Austin Christofferson, Amrita Krishnan, Jonathan J Keats, Alex E. Pozhitkov, Nagarajan Vaidehi, Estelle Troadec, Joycelynne Palmer, Jihane Khalife, Enrico Caserta, Guido Marcucci, Corey Morales, Emine Gulsen Gunes
Rok vydání:	2019
Předmět:	Drug synergism Proto-Oncogene Proteins c-myc Mice chemistry.chemical_compound Proto-Oncogene Proteins c-pim-1 In vivo hemic and lymphatic diseases Teriflunomide Tumor Cells Cultured medicine Animals Humans Enzyme Inhibitors Lenalidomide Active metabolite Leflunomide Drug Synergism Hematology Stimulus Report chemistry Pim kinases Cancer research Drug Therapy Combination Multiple Myeloma Combination method medicine.drug
Zdroj:	Blood Advances. 3:1027-1032
ISSN:	2473-9537 2473-9529
Popis:	Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8baa13a1c126dc88b70a6953690f13 https://doi.org/10.1182/bloodadvances.2018027227 Zobrazit plný text záznamu